0 0 0 0 0 0 0.0254173934712184 0.0254173934712184
Sign Up Today X
Thanks for submitting the form.
Stockreport

Incyte Reports 2019 Second Quarter Financial Results and Provides Updates on Key Clinical Programs

Incyte Corporation (INCY)  More Company Research Source: Business Wire
Last incyte corporation earnings: 2/13 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: incyte.com/ir/investor-overview.aspx
Total product and royalty revenues of $510 million (+21% vs. Q2 2018) and Jakafi® (ruxolitinib) revenues of $410 million (+18% vs. Q2 2018) for the quarter ended June 30, 2019; raising the bottom end of full year 2019 Jakafi revenue guidance to a new range of $1.61-1.65 billionAccomplished multiple key development goals for H1 2019, including FDA approval of Jakafi for steroid-refractory acute graft-versus-host disease (GVHD) and the presentation of clinically meaningful data from ruxolitinib cream in patients with vitiligoConference Call and Webcast Scheduled Today at 8:00 a.m. EDT WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Corporation (Nasdaq:INCY) today reports 2019 second quarter financial results and provides a status update on the Company’s development portfolio.“Revenue growth continues to be strong, and we are pleased that Jakafi is also now available as an approved therapeutic option for patients with steroid-refractory acute GVHD,” stated Hervé Hoppenot, Chief Executive Of [Read more]
IMPACT SNAPSHOT EVENT TIME: INCY
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
INCY alerts
from News Quantified
INCY
NEWS
INCY
Earnings
INCY
Analyst Actions
INCY
SEC Filings
Stockreport

Incyte Reports 2019 Second Quarter Financial Results and Provides Updates on Key Clinical Programs

Incyte Corporation  (INCY) 
More Company Research Source: Business Wire
Last incyte corporation earnings: 2/13 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: incyte.com/ir/investor-overview.aspx
Total product and royalty revenues of $510 million (+21% vs. Q2 2018) and Jakafi® (ruxolitinib) revenues of $410 million (+18% vs. Q2 2018) for the quarter ended June 30, 2019; raising the bottom end of full year 2019 Jakafi revenue guidance to a new range of $1.61-1.65 billionAccomplished multiple key development goals for H1 2019, including FDA approval of Jakafi for steroid-refractory acute graft-versus-host disease (GVHD) and the presentation of clinically meaningful data from ruxolitinib cream in patients with vitiligoConference Call and Webcast Scheduled Today at 8:00 a.m. EDT WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Corporation (Nasdaq:INCY) today reports 2019 second quarter financial results and provides a status update on the Company’s development portfolio.“Revenue growth continues to be strong, and we are pleased that Jakafi is also now available as an approved therapeutic option for patients with steroid-refractory acute GVHD,” stated Hervé Hoppenot, Chief Executive Of [Read more]
IMPACT SNAPSHOT
EVENT TIME:
INCY
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Don't Miss Out On The Next BIG Stock Move
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS